Cecilia Pessoa Gingerich

Following the completion of 2 pivotal trials, a new drug application for VP-102 will be submitted later this year.

Originally approved in 2013, the MitraClip is now approved for treating certain cases of secondary mitral regurgitation.

The Venovo venous stent is the first indicated to treat this condition.

Recalls on Diovan (valsartan) began last July when the FDA detected trace amounts of a probable carcinogen in certain lots of the blood pressure drug.

An FDA decision on the application is expected by December 27, 2019.

In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.

Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.

Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.

The supplemental BLAs seek to expand onabotulinumtoxinA label to treat pediatric patients with upper and lower limb spasticity.

Confocal microscopy is especially useful for diagnosing pigmented lesions, moles, melanoma, and basal cell carcinoma.

Galcanezumab was previously given a Breakthrough Therapy Designation for this indication.

Confocal microscopy is an emerging technique that can offer a non-invasive alternative to biopsy.

The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.

Aside from the efficacy and safety of risankizumab, Gordon addresses the convenience, ease of use, and persistence of efficacy for patients with psoriasis.

Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.

The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.

Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.

This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.

Patrick Burnett shares about the secondary endpoints and safety data of the CAMP 1 & 2 clinical trials.

The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.

Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.

Though there are few treatments for pemphigus vulgaris, a rare disease, the Believe-PV trial of PRN1008 raises the possibility of a new, better option.

Compared to standard cleansers and moisturizers, natural versions for sensitive skin provided benefits to patients with rosacea who were also taking prescription treatments.

In this analysis, brodalumab was successful in treating patients who had a psoriasis diagnosis for

A meta-analysis of studies found that treatment with platelet-rich plasma improves androgenetic alopecia, scarring, and other dermatologic conditions.

A large retrospective study of patients with acne found no significant association between isotretinoin exposure and depression.

In this phase 3 study, dupilumab improved outcomes for patients with recurring severe chronic rhinosinusitis with nasal polyps.

Patients who incorporated small amounts of peanut into their diet experienced increased quality of life.

Mothers reported breastfeeding infants who reacted to food allergen exposure via breastmilk for significantly longer than infants who did not react.

This analysis of the phase 3 LIBERTY ASTHMA QUEST study analyzed data for patients with and without allergic rhinitis.